TLDR

Continuous manufacturing (CM) produces pharmaceutical product in an uninterrupted stream rather than in discrete batches. FDA has issued guidance supporting the technology, and ICH Q13 — finalized in 2023 — provides the international framework for CM implementation and quality system requirements. For quality teams, CM introduces fundamentally different process monitoring, batch definition, and control strategy requirements that a traditional batch-oriented QMS is not designed to handle. Understanding those differences is the first step to building a quality system that supports CM without creating compliance gaps.

What continuous manufacturing is and why it matters

In batch manufacturing, raw materials are loaded, processed, and released as a defined lot. The batch is a unit of production with a start, an end, and a defined set of records. In continuous manufacturing, materials flow through the process without discrete starts and stops. Product is manufactured in a continuous stream, and the “batch” is defined differently — by time, by mass of material processed, or by some other operational boundary that the manufacturer defines and justifies to the regulator.

FDA has been actively encouraging CM adoption in pharmaceutical manufacturing for over a decade. The agency’s interest is straightforward: CM processes, when properly monitored and controlled, can produce more consistent product than batch processes because they eliminate the scale-up discontinuities and between-batch variability that are inherent in batch production. CM also enables faster manufacturing cycles, smaller facility footprints, and more responsive supply chains.

Johnson & Johnson received the first FDA approval for a solid oral dosage form product manufactured by continuous manufacturing in 2016. Since then, the number of approved CM products has grown, and FDA has approved CM for an expanding range of product types and dosage forms. [Source: FDA Guidance for Industry — Advancement of Emerging Technology Applications, 2017]

ICH Q13: the international framework for continuous manufacturing

ICH Q13 — “Continuous Manufacturing of Drug Substances and Drug Products” — was finalized by the International Council for Harmonisation in November 2022 and adopted by FDA, EMA, and other major regulatory agencies in 2023. It is the primary international guidance document governing CM implementation and quality system requirements for pharmaceuticals.

ICH Q13 covers CM for both drug substance (API) and drug product manufacturing. It addresses the key quality science concepts that distinguish CM from batch manufacturing: the control strategy, real-time release testing, the integrated process monitoring approach, and the definition and justification of the CM batch. [Source: ICH Q13 Guideline]

The guidance makes clear that the fundamental quality principles — process understanding, risk-based control, data integrity — are the same for CM as for batch manufacturing. What changes is how those principles are implemented in a process that runs continuously rather than in discrete units.

How CM changes the quality system

Batch definition

In a batch process, the batch is defined by the manufacturing cycle: everything produced from a defined set of inputs in a single manufacturing run. In CM, the manufacturer must define what constitutes a batch, justify that definition in the regulatory submission, and design the quality system to manage it. A CM batch might be defined as a specific duration of continuous operation (e.g., 24 hours of production), a defined mass of output, or a segment of a continuous run bounded by specific operational events.

The batch definition has direct implications for every batch-associated quality record: batch records, release testing records, certificates of conformance, and the nonconformance records that reference specific batch numbers. The quality system must be designed to generate and manage these records consistently with the approved batch definition.

Control strategy and real-time monitoring

ICH Q13 emphasizes that CM requires a robust control strategy — a defined set of controls that assure product quality throughout the continuous process. The control strategy for a CM process typically relies much more heavily on real-time process analytical technology (PAT) measurements than a batch process does. Rather than testing a sample of finished product against specification, CM quality assurance often involves continuous measurement of critical quality attributes during production, using spectroscopic or other inline analytical methods.

Real-time release testing (RTRT), where finished product is released based on real-time process and analytical data rather than traditional end-product testing, is a common feature of CM quality systems. RTRT requires regulatory approval and a validated analytical strategy, but it offers significant efficiency advantages — particularly for products with long end-product testing cycles.

The quality system must support the control strategy: capturing, storing, and making available the continuous stream of process data that demonstrates the process was in a state of control throughout the production run. This is a data management challenge at a scale that traditional paper-based or batch-oriented QMS platforms are not designed for.

Diversion and rejection of nonconforming material

In batch manufacturing, a nonconforming lot is identified, segregated, and submitted to the Material Review Board for disposition. In CM, nonconforming material must be diverted in real time — before it has a chance to mix with conforming product or continue through the process. This requires automated diversion capabilities built into the manufacturing system, triggered by the real-time process monitoring.

The quality system must document the diversion event: what triggered it, when it occurred, what quantity of material was diverted, and the disposition of the diverted material. The deviation report for a CM diversion event looks different from a traditional nonconforming lot record, but the underlying documentation requirements are the same — the event must be recorded, reviewed, and connected to any required corrective action.

Process validation

FDA’s 2011 process validation guidance describes three stages: process design, process qualification, and continued process verification. For CM, the continued process verification stage is especially important — and especially data-intensive. Because CM runs are long and the process is expected to operate continuously, the quality system must monitor process performance data continuously and flag deviations from the established control limits.

ICH Q13 provides specific guidance on process qualification for CM, including considerations for how to demonstrate process capability at the scale of continuous production rather than across a small number of discrete qualification batches. The statistical framework for CM process qualification is more sophisticated than for batch processes, and the quality team needs the analytical infrastructure to support it.

Data management requirements for a CM quality system

The data volume generated by a continuous manufacturing process is orders of magnitude larger than a batch process generating comparable product quantities. PAT instruments, process sensors, and environmental monitoring systems generate continuous data streams throughout the production run. All of that data is quality-relevant — it is the evidence that the control strategy was operating correctly throughout the run.

Managing this data requires a quality system with genuine data management capabilities: the ability to ingest large data streams from connected instruments, store them with appropriate metadata and timestamps, make them searchable and accessible for batch review and regulatory inspection, and connect them to the batch records and deviation records that reference specific time periods or process events.

Data integrity requirements apply to CM data with the same force as to any other quality-critical record. FDA expects that CM process data is attributable, legible, contemporaneous, original, and accurate (ALCOA). For continuous data streams from automated instruments, this means the system capturing the data must have validated data integrity controls, including protection against alteration and a complete audit trail.

Common quality system gaps for companies adopting CM

Organizations transitioning from batch to continuous manufacturing often find that their existing quality system was designed around batch concepts and does not map cleanly to CM requirements. The most common gaps include the following.

Batch record templates designed for discrete lots. A CM batch record needs to capture continuous process data over a defined time window, not a set of discrete manufacturing steps with individual sign-offs. Batch record templates designed for batch manufacturing require significant redesign for CM.

Nonconformance processes that assume discrete lots. Traditional nonconformance workflows are designed around identifiable lots that can be segregated and held. CM nonconformances require a different workflow that accounts for real-time diversion, continuous process recovery, and the documentation of which output was affected by a process excursion during a continuous run.

Change control processes that do not account for continuous operation. In batch manufacturing, a process change is implemented between batches. In CM, implementing a change requires careful consideration of how to manage the transition in a continuously operating system. The change control process and its documentation must reflect this complexity.

Insufficient data management infrastructure. The volume and velocity of CM process data typically exceeds what paper-based systems or basic electronic QMS platforms were designed to handle. Organizations adopting CM typically need to invest in data infrastructure that can manage continuous data streams alongside their traditional quality records.

How a cloud-based eQMS supports continuous manufacturing quality

A modern cloud-based eQMS provides several capabilities that are particularly valuable for CM quality management. Real-time data integration from connected manufacturing systems enables the quality team to monitor process performance as the run progresses, not just after the fact. Configurable batch record templates can be designed to match the specific batch definition used in the CM process. Deviation workflows can be configured to handle the diversion-and-recovery pattern characteristic of CM excursions.

Cloudtheapp’s platform includes 60+ applications covering quality, compliance, and operations management — all on a single validated system. The platform’s integration tools connect with MES, LIMS, and PAT data systems to consolidate the data streams that CM quality management requires. The no-code configuration capability allows quality teams to adapt batch record formats, deviation workflows, and control chart parameters to the specific requirements of their CM process without requiring IT development resources.

For regulated pharmaceutical manufacturers moving into continuous manufacturing, the quality system is not a secondary consideration — it is central to the regulatory approval pathway. A platform that can handle the data volume, the workflow complexity, and the documentation requirements of CM, while maintaining 21 CFR Part 11 compliance and ISO 13485 alignment, removes one significant barrier to CM adoption.

To see how Cloudtheapp supports continuous manufacturing quality programs, schedule a demo with the team.

Regulatory submissions for continuous manufacturing

For new product submissions that involve CM, FDA expects the submission to address the specific quality considerations described in ICH Q13: the batch definition and justification, the control strategy description, the process monitoring approach, the real-time release testing strategy (if applicable), and the approach to process validation including continued process verification.

For existing products that a company wants to transition from batch to CM, a prior approval supplement (PAS) or comparable regulatory mechanism is required. The supplement must demonstrate that the CM process produces product of equivalent or superior quality to the batch process and that the quality system is appropriately adapted to manage CM-specific quality requirements.

FDA has an Emerging Technology Program specifically designed to support early engagement with companies developing novel manufacturing approaches, including CM. Early engagement through this program can significantly reduce the regulatory uncertainty associated with first-of-kind CM implementations. [Source: FDA Emerging Technology Program]

Conclusion

Continuous manufacturing changes the practical reality of pharmaceutical quality management in ways that go beyond updating a few procedures. The batch definition, the control strategy, the real-time monitoring requirements, the data management challenge, and the deviation workflows all require substantive redesign for CM. Organizations that understand these requirements — and invest in the quality system infrastructure to support them — will be better positioned to realize the manufacturing flexibility and product quality benefits that continuous manufacturing offers. A modern cloud-based eQMS that can handle the data complexity and workflow requirements of CM is a necessary part of that infrastructure.